Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
Patients with refractory and relapse leukemia had poor outcome even with allogeneic stem cell
transplantation. In our previous retrospective study, the overall survival is 14.6+/-8.8%
while 90% patients eventually relapsed with marrow ablative conditioning mostly standard
iv-Bu-Cy or Cy-TBI. The accumulated TRM is 29.5+/-11.5%. Thus our data suggested that the
conventional transplantation approach may not be able to overcome the refractory disease. A
new strategy to combined a low dose regimen following intensive chemotherapy for tumor
reduction seems to be effect in both relapsed. high-risk and refractory AML or ALL. In this
study, we focus on a new treatment strategy for particular refractory AML patients.